《中国心力衰竭诊断和治疗指南2018》药物更新透视
|
摘要
心力衰竭是各种心脏疾病的严重表现或晚期阶段,被称为心血管领域最后的战场。《中国心力衰竭诊断和治疗指南2018》在2014年版指南基础上,结合新的循证医学证据和我国国情,对心力衰竭分类、诊断、预防、治疗和管理等内容均作了全面清晰地阐述和推荐。该文对治疗药物部分的更新进行综述。
Heart failure is a serious or advanced stage of various heart diseases,which is identified as the final battleground in the cardiovascular field. The 2018 guidelines for the diagnosis and treatment of heart failure,which are based on the 2014 guidelines in China with new evidence and clinical status,aimed to provide practical,evidence-based guidelines for the diagnosis,classification,prevention,treatment and management of heart failure. This study reviewed updates of pharmacologic therapy in the guideline.
Heart failure is a serious or advanced stage of various heart diseases,which is identified as the final battleground in the cardiovascular field. The 2018 guidelines for the diagnosis and treatment of heart failure,which are based on the 2014 guidelines in China with new evidence and clinical status,aimed to provide practical,evidence-based guidelines for the diagnosis,classification,prevention,treatment and management of heart failure. This study reviewed updates of pharmacologic therapy in the guideline.
引文
[1]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要[J].中国循环杂志,2018,33(1):1-8.
[2]中华医学会心血管病学分会心力衰竭学组,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[4]国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,9(8):19-66.
[5]陈文文,刘燕琳,李振山,等.沙库巴曲缬沙坦在心衰治疗中的应用:从临床试验到真实世界[J].中国医院药学杂志,2018,21(38):2286-2290.
[6]MCMURRAY J J,PACKER M,DESAI A S,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[7]BASTIEN N,HADDAD H,BERGERON S,et al.The PARA-SAIL study-patient reported outcomes from the Canadian real-world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction[J].Can JCardiol,2017,33(10):S162-S163.
[8]MOQENSEN U M,KOBER L,KRISTENSEN S L,et al.The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF[J].Am Heart J,2017,188(6):35-41.
[9]PONIKOWSKI P,VOORS A A,ANKER S D,et al.2016ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,37(27):2129-2200.
[10]YANCY C W,JESSIP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHAguideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-161.
[11]GHEORGHIADE M,VAN VELDHUISEN D J,COLUCCI WS.Contemporary use of digoxin in the management of cardiovascular disorders[J].Circulation,2006,113(21):2556-2564.
[12]PACKER M,GHEORGHIADE M,YOUNG J B,et al.Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors[J].NEngl J Med,1993,329(1):1-7.
[13]TRIAL M.The effect of digoxin on mortality and morbidity in patients with heart failure[J].N Engl J Med,1997,336(8):525-533.
[14]LOPES R D,RORDORF R,DE FERRARI G M,et al.Digoxin and mortality in patients with atrial fibrillation[J].J Am Coll Cardiol,2018,71(10):1063-1074.
[15]PACKER M,COATS A J,FOWLER M B,et al.Effect of carvedilol on survival in severe chronic heart failure[J].NEngl J Med,2001,344(22):1651-1658.
[16]ZHANG Y,ZHANG J,BUTLER J,et al.Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure(China-HF)registry[J].J Card Fail,2017,23(12):868-875.
[17]LI X,ZHANG J,HUANG J,et al.A multicenter,randomized,double-blind parallel-group,placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J].J Am Coll Cardiol,2013,62(12):1065-1072.
[2]中华医学会心血管病学分会心力衰竭学组,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[4]国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,9(8):19-66.
[5]陈文文,刘燕琳,李振山,等.沙库巴曲缬沙坦在心衰治疗中的应用:从临床试验到真实世界[J].中国医院药学杂志,2018,21(38):2286-2290.
[6]MCMURRAY J J,PACKER M,DESAI A S,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[7]BASTIEN N,HADDAD H,BERGERON S,et al.The PARA-SAIL study-patient reported outcomes from the Canadian real-world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction[J].Can JCardiol,2017,33(10):S162-S163.
[8]MOQENSEN U M,KOBER L,KRISTENSEN S L,et al.The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF[J].Am Heart J,2017,188(6):35-41.
[9]PONIKOWSKI P,VOORS A A,ANKER S D,et al.2016ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,37(27):2129-2200.
[10]YANCY C W,JESSIP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHAguideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-161.
[11]GHEORGHIADE M,VAN VELDHUISEN D J,COLUCCI WS.Contemporary use of digoxin in the management of cardiovascular disorders[J].Circulation,2006,113(21):2556-2564.
[12]PACKER M,GHEORGHIADE M,YOUNG J B,et al.Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors[J].NEngl J Med,1993,329(1):1-7.
[13]TRIAL M.The effect of digoxin on mortality and morbidity in patients with heart failure[J].N Engl J Med,1997,336(8):525-533.
[14]LOPES R D,RORDORF R,DE FERRARI G M,et al.Digoxin and mortality in patients with atrial fibrillation[J].J Am Coll Cardiol,2018,71(10):1063-1074.
[15]PACKER M,COATS A J,FOWLER M B,et al.Effect of carvedilol on survival in severe chronic heart failure[J].NEngl J Med,2001,344(22):1651-1658.
[16]ZHANG Y,ZHANG J,BUTLER J,et al.Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure(China-HF)registry[J].J Card Fail,2017,23(12):868-875.
[17]LI X,ZHANG J,HUANG J,et al.A multicenter,randomized,double-blind parallel-group,placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J].J Am Coll Cardiol,2013,62(12):1065-1072.